A detailed history of Profund Advisors LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Profund Advisors LLC holds 10,586 shares of SUPN stock, worth $406,502. This represents 0.01% of its overall portfolio holdings.

Number of Shares
10,586
Previous 11,194 5.43%
Holding current value
$406,502
Previous $299,000 10.37%
% of portfolio
0.01%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$25.77 - $35.16 $15,668 - $21,377
-608 Reduced 5.43%
10,586 $330,000
Q2 2024

Aug 13, 2024

BUY
$25.99 - $33.85 $118,072 - $153,780
4,543 Added 68.31%
11,194 $299,000
Q1 2024

May 08, 2024

SELL
$27.11 - $35.17 $84,528 - $109,660
-3,118 Reduced 31.92%
6,651 $226,000
Q4 2023

Feb 14, 2024

BUY
$22.72 - $29.68 $2,476 - $3,235
109 Added 1.13%
9,769 $282,000
Q3 2023

Nov 13, 2023

BUY
$27.57 - $32.91 $40,086 - $47,851
1,454 Added 17.72%
9,660 $266,000
Q2 2023

Aug 10, 2023

SELL
$29.91 - $38.73 $11,425 - $14,794
-382 Reduced 4.45%
8,206 $246,000
Q1 2023

May 11, 2023

BUY
$34.93 - $42.03 $299,978 - $360,953
8,588 New
8,588 $311,000
Q1 2019

May 15, 2019

SELL
$32.77 - $41.99 $241,613 - $309,592
-7,373 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$30.84 - $49.51 $77,809 - $124,913
-2,523 Reduced 25.5%
7,373 $245,000
Q3 2018

Nov 13, 2018

SELL
$42.7 - $56.55 $60,377 - $79,961
-1,414 Reduced 12.5%
9,896 $498,000
Q2 2018

Aug 13, 2018

BUY
$44.1 - $59.85 $51,244 - $69,545
1,162 Added 11.45%
11,310 $677,000
Q1 2018

May 14, 2018

BUY
$37.15 - $46.9 $101,010 - $127,521
2,719 Added 36.6%
10,148 $465,000
Q4 2017

Feb 14, 2018

BUY
$36.4 - $42.6 $40,294 - $47,158
1,107 Added 17.51%
7,429 $296,000
Q3 2017

Nov 13, 2017

SELL
$36.75 - $49.65 $107,346 - $145,027
-2,921 Reduced 31.6%
6,322 $253,000
Q2 2017

Aug 11, 2017

BUY
N/A
9,243
9,243 $398,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $2.05B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.